Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

about

Evidence for the persistence of an active endogenous retrovirus (ERVE) in humans.Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities

P2860

Q42192642-93504157-3480-41DC-A662-8C92BB7496BA Q57069976-CC8A4EC7-493B-42FE-8AA8-F8D25A8DE325

P2860

Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Item

http://www.wikidata.org/entity/Q37327244

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Preclinical and clinical exper ...... ukemias and myeloid disorders.

@en

Preclinical and clinical exper ...... ukemias and myeloid disorders.

@nl

type

Item

label

Preclinical and clinical exper ...... ukemias and myeloid disorders.

@en

Preclinical and clinical exper ...... ukemias and myeloid disorders.

@nl

prefLabel

Preclinical and clinical exper ...... ukemias and myeloid disorders.

@en

Preclinical and clinical exper ...... ukemias and myeloid disorders.

@nl

P1476

Preclinical and clinical exper ...... ukemias and myeloid disorders.

@en

P2860

Essential thrombocythemia

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

Proposals for the classification of the myelodysplastic syndromes

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Overriding imatinib resistance with a novel ABL kinase inhibitor

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

P304

617-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LEUKRES.2008.10.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Srdan Verstovsek

P577

2008-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19013641

http://www.w3.org/2001/XMLSchema#string

P932

4428150

http://www.w3.org/2001/XMLSchema#string

Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

about

P2860

P2860

Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932